• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Drugs of today: Medicamentos de actualidad >Sarecycline hydrochloride for the treatment of acne vulgaris
【24h】

Sarecycline hydrochloride for the treatment of acne vulgaris

机译：Sarecycline盐酸盐用于痤疮寻常痤疮

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Sarecycline hydrochloride (Seysara) is a novel, narrow-spectrum tetracycline derivative approved by the U.S. Food and Drug Administration (FDA) in October 2018 for the treatment of inflammatory non-nodular moderate to severe acne vulgaris. It was initially developed by Paratek Pharmaceuticals, Inc. (U.S.) and Allergan plc (U.S.), which later was acquired by Almirall S.A. (Barcelona, Spain). Almirall A. obtained U.S. FDA approval of oral sarecycline tablets under the trade name Seysara. Sarecycline exhibits antibacterial activity against important skin/soft tissue pathogens with targeted activity against Cutibacterium acnes-an anaerobic Gram-positive bacterium linked with acne lesions- and also exerts anti-inflammatory effects as do other tetracyclines used in the treatment of acne vulgaris. Interestingly, unlike the broad-spectrum tetracyclines, sarecycline is less potent against aerobic Gram-negative bacilli and anaerobic bacteria associated with endogenous intestinal microbial flora. This provides it with a more specific antibacterial spectra with lower chances of adverse off-target antibacterial effects, thus making it a promising choice of treatment over others in its class. It has also demonstrated low propensity to resistance as compared with other tetracyclines and is also active against tetracycline-resistant Staphylococcus a u reus as well as erythromycin- and clindamycin-resistant C. acnes strains. Sarecycline has successfully undergone numerous phase I, phase II and three phase III studies establishing it as a well-tolerated once-daily oral drug available as a tablet for the treatment of patients 9 years of age or above.
机译：Sarecycline盐酸盐（Seysara）是由美国食品和药物管理局（FDA）批准的新型，狭窄的四环素衍生物，于2018年10月批准用于治疗炎症非结节中度至严重痤疮紫色。它最初由Paratek Pharmaceuticals，Inc。（美国）和allergan Plc（美国）开发，后来是由Almirall S.A.（巴塞罗那，西班牙）收购的。 Almirall A.获得的美国FDA在商品名Seysara下批准口服萨索霉素片剂。 Sarecycline表现出针对具有针对性痤疮的靶向活性的重要皮肤/软组织病原体的抗菌活性 - 与痤疮病变有关的厌氧革兰氏阳性细菌 - 并且还施加抗炎作用，以及用于治疗痤疮的其他四环素。有趣的是，与广谱四环素不同，萨米霉素对与内源性肠道微生物菌群相关的有氧革兰氏阴性杆菌和厌氧细菌的有效性较小。这提供了一种更具体的抗菌光谱，具有较低的抗菌抗菌效应的可能性较低，从而使其在课堂上对他人进行了很有希望的选择。与其他四环素相比，它还表现出低的抗性倾向，并且还具有抗四环素抗性金葡萄球菌以及红霉素和克林霉素抗性C.痤疮菌株。 Sarecycline已经成功地经历了许多阶段I，II期和三阶段III研究，将其作为一种耐受良好的一次每日口服药物，作为一种用于治疗9岁或以上患者的片剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号